CAS No.51264-14-3,Amsacrine Suppliers

Products Categories

Pharmaceutical (44)
Organic Chemicals (10)
Others (6)
Reagent (2)
Basic Inorganic Chemicals (2)
Catalyst and Auxiliary (1)
Materials (1)

Basic Information

Molecular Structure:
CAS No.:	51264-14-3
Name:	Amsacrine
Article Data:	8

Formula:	C21H19 N3 O3 S
Molecular Weight:	393.466
Synonyms:	4'-(9-Acridinylamino)methanesulfon-m-anisidide;AMSA; Acridinylanisidide; Amekrin; Amsacrine; Amsidil; Amsidine; Amsidyl; CI880; Lamasine; N-[4-(9-Acridinylamino)-3-methoxyphenyl]methanesulfonamide; NSC156303; NSC 249992; SN 11841; SN 21429; m-AMSA; m-Amsacrine
EINECS:	257-094-3
Density:	1.398 g/cm³
Melting Point:	230-240oC
Boiling Point:	563 °C at 760 mmHg
Flash Point:	294.3 °C
Appearance:	white solid
Safety:	Poison by ingestion, intravenous, subcutaneous, and intraperitoneal routes. Human systemic effects by intravenous route: nausea or vomiting, thrombosis distant from injection site, and bone marrow changes. An experimental teratogen. Other experimental reproductive effects. Mutation data reported. When heated to decomposition it emits very toxic fumes of NO_x and SO_x.
PSA:	88.70000
LogP:	5.73850

Total:60 Page 1 of 2 1 2 Next>>

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 51264-14-3

Chemistry

IUPAC Name: N-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide
Synonyms: 4'-(Acridinylamino)methanesulfon-m-anisidide ; AMSA, M- ; Methanesulfonamide, N-(4-(9-acridinylamino)-3-methoxyphenyl)- ; Methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]- ; N-[4-(9-Acridinylamino)-3-methoxuphenyl]methanesulfonamide ; N-[4-(9-Acridinylamino)-3-methoxyphenyl]methanesulfonamide ; N-[4-(acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide ; N-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide
Product Categories: Pharmaceutical material and intermeidates
Molecular Structure of 4'-(9-Acridinylamino)methanesulphon-m-anisidide (CAS NO.51264-14-3) :
Molecular Formula of 4'-(9-Acridinylamino)methanesulphon-m-anisidide (CAS NO.51264-14-3) : C₂₁H₁₉N₃O₃S
Molecular Weight of 4'-(9-Acridinylamino)methanesulphon-m-anisidide (CAS NO.51264-14-3) : 393.46
CAS NO: 51264-14-3
EINECS: 257-094-3
Mol File: 51264-14-3.mol
Index of Refraction: 1.722
Surface Tension: 65.6 dyne/cm
Density: 1.398 g/cm³
Flash Point: 294.3 °C
Enthalpy of Vaporization: 84.62 kJ/mol
Boiling Point: 563 °C at 760 mmHg
Vapour Pressure: 1.06E-12 mmHg at 25°C

Uses

4'-(9-Acridinylamino)methanesulphon-m-anisidide (CAS NO.51264-14-3) is used as Acridine anti-cancer drugs, mainly for a cellular inhibitor. The role of it's theory is similar to anthracycline. It is mainly used for acute lymphoblastic leukemia and bone marrow cells in treatment.

Production

Reaction of O-methoxy-p-nitroaniline with chloride ,protect amino-amidation , reduce the nitro to amino, which is amino-acylation by sulfonyl chloride to form sulfonyl amino, and then selectively hydrolysis, take off the fist amino-protecting groups, at last reaction with 9 - chloro-acridine, 4'-(9-Acridinylamino)methanesulphon-m-anisidide (CAS NO.51264-14-3) is obtained .

Toxicity Data With Reference

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
dog	LD50	intravenous	6250ug/kg (6.25mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: DYSPNEA	Cancer Treatment Reports. Vol. 64, Pg. 855, 1980.
dog	LD50	oral	50mg/kg (50mg/kg)	BEHAVIORAL: FOOD INTAKE (ANIMAL) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" GASTROINTESTINAL: NAUSEA OR VOMITING	Cancer Treatment Reports. Vol. 66, Pg. 1939, 1982.
human	TDLo	intravenous	12mg/kg (12mg/kg)	VASCULAR: THROMBOSIS DISTANT FROM INJECTION SITE GASTROINTESTINAL: NAUSEA OR VOMITING BLOOD: OTHER CHANGES	Cancer Research. Vol. 38, Pg. 3712, 1978.
man	LDLo	intravenous	5405ug/kg/3H- (5.405mg/kg)	BLOOD: CHANGES IN BONE MARROW NOT INCLUDED ABOVE	Archives of Internal Medicine. Vol. 143, Pg. 165, 1983.
monkey	LDLo	intravenous	10400ug/kg (10.4mg/kg)	BLOOD: CHANGES IN BONE MARROW NOT INCLUDED ABOVE	Pharmacy International. Vol. 7, Pg. 3, 1986.
mouse	LD50	intraperitoneal	15470ug/kg (15.47mg/kg)		National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,
mouse	LD50	intravenous	33700ug/kg (33.7mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: DYSPNEA	Cancer Treatment Reports. Vol. 64, Pg. 855, 1980.
mouse	LD50	oral	53420ug/kg (53.42mg/kg)		National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,
mouse	LD50	subcutaneous	110mg/kg (110mg/kg)		National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,

Consensus Reports

EPA Genetic Toxicology Program.

Safety Profile

Poison by ingestion, intravenous, subcutaneous, and intraperitoneal routes. Human systemic effects by intravenous route: nausea or vomiting, thrombosis distant from injection site, and bone marrow changes. An experimental teratogen. Other experimental reproductive effects. Mutation data reported. When heated to decomposition it emits very toxic fumes of NO_x and SO_x.
RIDADR 3249
HazardClass 6.1(b)
PackingGroup III